Following first-line therapy with corticosteroids, CTLA4 inhibitor–induced colitis recurs in about 44% of patients, and PD1/PDL1 inhibitor–induced colitis recurs in about 34% of patients [7]. This evidence concerns the gene CD274 and colitis.